



Supplemental Figure 1. Identification and confirmation of *CTSB* (exon1)-*ALK* (exon16) fusion. (A) Analysis of mRNA expression levels of individual *CTSB* and *ALK* exons using RNA-Seq data showed overexpression of *ALK* exons 16 to 29 downstream of the fusion point. Each box represents an exon, and the boxes are colored according to the logarithm of their expression levels as measured in RPKMs (reads per kilobase per million reads). (B) RT-PCR (left) and Sanger sequencing (right) confirmation of *CTSB* (exon1)-*ALK* (exon16) fusion. L, 100-bp ladder; T, tumor; N, normal tissue; NC, negative control; ex, exon. (C) Schematic representation of the predicted protein containing the transmembrane domain (TM) and tyrosine kinase (TK) domain of *ALK*. Propeptide, Peptidase C1A-propeptide; Peptidase C1A, c-terminal; MAM, merpin, A5 protein and receptor protein tyrosine mu; LB, ligand binding domain.